Research
Hormonal
Semaglutide 2.4 mg improves cardiometabolic risk factors, including blood pressure, lipids, glycated hemoglobin, and C-reactive protein, extending benefits beyond weight loss alone.
Beyond weight loss, semaglutide 2.4 mg helps improve blood pressure, cholesterol, blood sugar control, and inflammation markers. This makes it particularly beneficial for patients with obesity who also have related health risks like hypertension or diabetes.
StrongSupportsHIGH confidence
Improvements in blood pressure, lipids, glycated hemoglobin, and C-reactive protein, a marker of inflammation, were observed across the STEP 1–5 trials, demonstrating that the beneficial effects of once-weekly semaglutide 2.4 mg extend beyond weight loss alone.
Why this rating
Based on phase 3 STEP 1-5 trials.
Source
Integrating semaglutide into obesity management – a primary care perspective
Janine V. Kyrillos et al. · Postgraduate Medicine · 2022
DOI 10.1080/00325481.2022.2149964
narrative_reviewCited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Once-weekly subcutaneous semaglutide 2.4 mg, used as an adjunct to lifestyle modification, produces clinically significant and sustained mean body weight reductions of 14–16% in adults without type 2 diabetes and 9.6% in adults with type 2 diabetes.Strong
- Obesity is a chronic disease characterized by complex abnormalities in body weight regulation, and weight-related stigmatization is a key barrier to effective care.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →